Ni Ming-Ming, Yang Shu-Ting, Sun Jie-Yu, Wu Wen-Wen, Li Man, Gu Wei, Ji Xing
Department of Pharmacy, Children's Hospital of Nanjing Medical University, Nanjing, China.
School of Pharmacy, Nanjing Medical University, Nanjing, China.
Gynecol Endocrinol. 2025 Dec;41(1):2500481. doi: 10.1080/09513590.2025.2500481. Epub 2025 May 5.
This study aimed to evaluate the short-term benefits of GnRHa therapy, with a specific focus on the first year of treatment, in girls diagnosed with idiopathic central precocious puberty (ICPP) after age 8, providing essential evidence to inform clinical decision-making.
Ninety-four female patients treated with GnRHa at Jiangsu Children's Medical Center from January 2018 to January 2021 were retrospectively reviewed. Patients were divided into two groups based on the age of treatment initiation: on or before age 8 (Group I) and over age 8 (Group II). Hormonal parameters, bone age (BA)/chronological age (CA) ratio, genital organ volume, predicted adult height (PAH), and body mass index (BMI) were assessed during the treatment period.
Treatment with GnRHa in girls with ICPP, whether administered before or after age 8, effectively inhibited puberty, slowed BA maturation, and led to an increase in PAH. Group I exhibited significantly better PAH improvement than Group II, with 50% surpassing a 5 cm increase in PAH compared to 25.9% in Group II. No significant changes in BMI were observed following treatment.
The findings of the study support the knowledge that GnRHa treatment is effective in height gain in girls with precocious puberty, especially if started before the age of 8 years.
本研究旨在评估促性腺激素释放激素类似物（GnRHa）治疗的短期益处，特别关注8岁后诊断为特发性中枢性性早熟（ICPP）的女孩治疗的第一年，为临床决策提供重要依据。
回顾性分析2018年1月至2021年1月在江苏省儿童医院接受GnRHa治疗的94例女性患者。根据开始治疗的年龄将患者分为两组：8岁及8岁以前（I组）和8岁以后（II组）。在治疗期间评估激素参数、骨龄（BA）/实际年龄（CA）比值、生殖器官体积、预测成年身高（PAH）和体重指数（BMI）。
ICPP女孩接受GnRHa治疗，无论在8岁之前还是之后给药，均能有效抑制青春期，减缓BA成熟，并导致PAH增加。I组的PAH改善明显优于II组，50%的患者PAH增加超过5厘米，而II组为25.9%。治疗后BMI未观察到显著变化。
该研究结果支持GnRHa治疗对性早熟女孩身高增长有效的观点，尤其是在8岁之前开始治疗。
